This article is more than 5 years old. Information may no longer be current.

iScience announces Medtronic investment for rapid commercialization of microcatheters

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

MENLO PARK, Calif. — iScience Interventional announced an investment by Medtronic to accelerate commercialization and further development of its microcatheter and imaging technologies, according to a news release.

"Microcatheters are rapidly redefining the treatment paradigm for a wide range of ocular diseases from glaucoma to macular degeneration," Michael F. Nash, president and CEO of iScience, said in the release. "We are excited to collaborate with Medtronic as we address some of the most significant intractable diseases of the eye."

iScience's microcatheter-based glaucoma procedure, canaloplasty, has become the standard of care for moderate to advanced glaucoma. The company's microcatheters are also being investigated in clinical trials for the treatment of retinal diseases.

"iScience has the potential to change how we address a wide range of ocular diseases," Steve Oesterle, MD, senior vice president for medicine and technology at Medtronic, said in the release. "The ability to deliver drugs, biologics, devices, and cell therapies directly to the site of the diseases may redefine how we manage several of the most significant sight-threatening conditions of the eye."